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Abstract Properties of the local internal environment of the adult brain are tightly controlled
providing a stable milieu essential for its normal function. The mechanisms involved in this
complex control are structural, molecular and physiological (influx and efflux transporters)
frequently referred to as the ‘blood–brain barrier’. These mechanisms include regulation of ion
levels in brain interstitial fluid essential for normal neuronal function, supply of nutrients,
removal of metabolic products, and prevention of entry or elimination of toxic agents. A key
feature is cerebrospinal fluid secretion and turnover. This is much less during development,
allowing greater accumulation of permeating molecules. The overall effect of these mechanisms
is to tightly control the exchange of molecules into and out of the brain. This review pre-
sents experimental evidence currently available on the status of these mechanisms in developing
brain. It has been frequently stated for over nearly a century that the blood–brain barrier is
not present or at least is functionally deficient in the embryo, fetus and newborn. We suggest
the alternative hypothesis that the barrier mechanisms in developing brain are likely to be
appropriately matched to each stage of its development. The contributions of different barrier
mechanisms, such as changes in constituents of cerebrospinal fluid in relation to specific features
of brain development, for example neurogenesis, are only beginning to be studied. The evidence
on this previously neglected aspect of brain barrier function is outlined. We also suggest future
directions this field could follow with special emphasis on potential applications in a clinical
setting.
(Received 13 January 2018; accepted after revision 12 March 2018; first published online 10 May 2018)
Corresponding author N. R. Saunders: Department of Pharmacology and Therapeutics, University of Melbourne,
Parkville, Victoria, 3010, Australia. Email: n.saunders@unimelb.edu.au
Abstract figure legend Barrier mechanisms in the developing brain. Blood–brain barrier (BBB), Blood–CSF barrier
(BCSFB) and CSF–brain barrier (CSFBB).
Gene abbreviations: (For gene products (proteins), capitals are used.) Cacn, calcium voltage-gated channel; Clcnka,
chloride voltage-gated channel Ka;Clic, chloride channel;Gypa, glycophorin A;Kcnh8, potassium voltage-gated channel
subfamilyHmember 8;Kcnk9, potassium two pore domain channel subfamily Kmember 9;Cacn, calcium voltage-gated
channel; Kcnmb1, potassium calcium-activated channel subfamily M regulatory beta subunit 1; Kcnmb2, potassium
calcium-activated channel subfamily M regulatory beta subunit 2; Scn, voltage gated sodium channels; Scnn1g, sodium
channel, nonvoltage-gated 1 gamma; Sparc, Secreted protein acidic and rich in cysteine; vamp, vesicle-associated
membrane proteins; Tmc5, transmembrane channel-like 5; Trpv, transient receptor potential cation channel; Wnt,
wingless-type MMTV (mouse mammary tumor virus) integration site.
Introduction
The internal environment of the adult brain is defined
and controlled by a series of mechanisms usually referred
to colloquially as the blood–brain barrier. However,
these are not unified identities, either in terms of their
anatomical situation and structure, or in terms of their
functional properties. The multifactorial characteristics
of brain–blood interfaces are the main reason why
misconceptions and controversies continue in the field
(see box). One of the main areas of dispute has been
the so-called ‘immaturity’ of brain barriers, especially the
blood–brain barrier proper (cerebral endothelial inter-
face), in the developing brain.
It has been widely believed for nearly a century that
these mechanisms in the fetal and newborn brain are
absent or poorly developed. This belief appears to stem
from misunderstandings and mistranslations of early
studies, not helped by some poorly designed experiments
(reviewed in detail in Saunders et al. 2014). In spite
of extensive evidence to the contrary, this belief still
persists (Allen, 2015; Oberdick et al. 2016; Panfoli et al.
2016; Amaraneni et al. 2017) with some new inventive
terms appearing that imply some level of dysfunction:
‘inefficient’ (Panfoli et al. 2016), ‘primitive’ (Zhao et al.
2015). In place of this rather un-illuminating view of
blood–brain barrier mechanisms in the developing brain,
we propose that the specific barrier mechanisms present
at any particular stage of brain development are ones that
are appropriate for that stage of its development. They
can thus be investigated in relation to specific features
of brain maturation, such as neurogenesis (Lehtinen
& Walsh, 2011; Lehtinen et al. 2013; Lun et al.
2015).
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Misconceptions and controversies discussed below
 Continued use of the term ‘immature’ to indicate a functional deficiency in brain barrier
mechanisms.
 Do the first blood vessels that grow into the brain anlage have functionally effective intercellular
tight junctions?
 Does increased apparent permeability (leakiness) to dyes and small molecular mass markers reflect
‘breakdown’ of tight junctions?
 Does greater accumulation of a molecule in developing brain and cerebrospinal fluid reflect greater
permeability of barriers in the developing brain?
 What is the role of astrocytes in formation (initiation) and maintenance of blood–brain barrier
properties?
 Permeability of the paracellular pathway.
In support of this proposition we summarize data that
have accumulated over the past few decades from studies
using classical physiological approaches and in more
recent years from the application ofmolecular techniques.
We also outline some key points in the biology of the field
that are still controversial (box above) and indicate where
this vital research may take us in the future.
Barrier interfaces between the brain and the rest of
the organism
The fundamental structural component of almost all of the
barrier interfaces is the tight junctions between the cells
forming the interface. There are at least six identifiable
barrier interfaces in the brain (including one that is
exclusive to the fetal brain). These are illustrated and
described in Fig. 1, with morphological details in Fig. 2.
In summary these barrier interfaces are:
(a) The blood–brain barrier (Figs 1A and 2Aa and b) is
situated between the lumen of cerebral blood vessels
and brain parenchyma. Tight junctions are present
between the endothelial cells restricting permeability
of the paracellular cleft (Brightman & Reese, 1969)
to an extent that is still controversial (see below);
however, the tight junctions in blood vessels of early
developing brain appear to be impermeable to even
very small molecules (Fig. 2A). Additional details are
in legends to Figs 1 and 2.
(b) The blood-cerebrospinal fluid barrier (Fig. 1B) in
the choroid plexus within each brain ventricle. The
barrier forming cells are the epithelial cells,whichhave
tight junctions at the apices of adjacent epithelial cells
forming the structural basis of this barrier; they pre-
vent penetration of even small molecules from blood
to cerebrospinal fluid (CSF; Fig. 2B). The blood vessels
in the stroma of the choroid plexus are fenestrated
and are thought not to form a barrier, although their
endothelial cells appear to contain some key efflux
transporters that prevent entry of many lipid-soluble
molecules into the brain and CSF (Møllga˚rd et al.
2017). Extracellular matrix basement membrane may
also contribute, but there are no astrocytic endfeet or
pericytes.
(c) Circumventricular organs (Fig. 1C). These comprise
the organum vasculosum laminae terminalis
(OVLT), subfornical organ, median eminence, sub-
commissural organ (SCO)–pineal complex and area
postrema. Apart from the SCO, which has a
normal blood–brain barrier, blood vessels in the
circumventricular organs have similar permeability
characteristics to vessels elsewhere in the body. This
allows feedback penetration of circulating peptide
hormones. However, these and other molecules
are prevented from entering the CSF by tanycytes,
connected by tight junctions between their apices; the
perivascular space is separated off by tight junctions
from the CSF milieu of the adjacent neuropil, as
illustrated in Fig. 2Ca and b for the subcommissural
organ (see Madsen & Møllga˚rd, 1979).
(d) Ependyma in adult brain (Figs 1D and 2D. Ependymal
cells are linked by gap junctions; there is unrestricted
exchange of even large molecules such as proteins
between CSF and brain interstitial space (Brightman
& Reese, 1969; Fossan et al. 1985).
(e) The embryonic CSF–brain barrier (Fig. 1E). This
is a transient barrier between the CSF and brain
parenchyma formed by strap junctions between
adjacent neuroepithelial cells (Fig. 2Ea and b;
Møllga˚rd et al. 1987) which restrict all but the
smallest lipid insoluble molecules from entering
the brain (Fossan et al. 1985; Whish et al. 2015).
Theydisappearprogressivelyduringdevelopment and
are no longer present when this interface becomes
ependyma (Fig. 2D; Møllga˚rd et al. 1987).
(f) The meningeal barrier (Fig. 1F). This consists of
three distinct interfaces: (i) blood–arachnoid–outer
CSF, (ii) blood–pia microvessel–outer CSF and
C© 2018 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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Figure 1. Schematic diagram (middle right) of the five main barrier interfaces (A–D and F) in the adult
and developing brain and an additional one present only in the embryo (E)
The barrier-forming cellular layers at each interface are coloured green.
A, the blood–brain barrier is situated at the level of cerebral blood vessels (BV). Tight junctions (tj, arrowhead)
are present between the endothelial cells (EC) restricting the paracellular cleft. AE, end feet from astroglial
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cells; bm, basement membrane; PC, pericytes. Other important components of this interface are a basement
membrane of extracellular matrix, within which are embedded pericytes (Engelhardt & Sorokin, 2009) surrounding
the endothelial cells (Daneman et al. 2010b, Errede et al. 2014). Astroglial end feet encircle cerebral blood
vessels during the first 2–3 weeks of postnatal development in rodents (Caley & Maxwell, 1970) although the
encirclement appears to be less complete than previously thought (Korogod et al. 2015). The contribution of
astrocytes to development and maintenance of barrier properties is controversial as will be discussed. These
cellular structures are known collectively as the neurovascular unit (Neuwelt, 2004). B, the blood–CSF barrier is
situated in the choroid plexus within each brain ventricle. Barrier-forming cells are the epithelial cells (CPE), which
have tight junctions at their apical side (CSF facing, arrowheads). Blood vessels (BV) are fenestrated and do not
form a barrier (arrows); apical microvilli increase exchange surface of epithelial cells to the internal CSF (i-CSF)
C, circumventricular organs (including median eminence, pineal gland, area postrema, subfornical organ). Blood
vessels have permeability characteristics similar to elsewhere in the body and have the functional property of
allowing feedback penetration of peptide hormones controlled by the hypothalamic–pituitary axis. These peptides
and other molecules are prevented from entering the CSF by tanycytes (TC), the specialized ependymal cells of
these brain areas, connected by tight junctions between their apices (arrowhead); entry into the rest of the brain
is prevented by tight junctions between astroglial cells (GC). Away from the tanycyte layer, ependymal cells lining
the ventricular system are linked by gap junctions that allow free exchange between the CSF and brain interstitial
fluid. D, ependyma in adult brain. Apart from areas where there are specialized tanycytes, ependymal cells are
linked by gap junctions that do not restrict exchange of even large molecules, such as proteins, between CSF
and interstitial space of brain (arrows). E, the embryonic CSF–brain barrier. In early brain development, strap
junctions (arrowheads) are present between adjacent neuroepithelial cells (NE); these form a barrier restricting the
movement of larger molecules, such as proteins, but not smaller molecules. F, the meningeal barrier is structurally
the most complex of all the brain barriers. Barrier-forming cells are the outer layer of the arachnoid membrane
(the arachnoid barrier cells; ABC); these have tight junctions (arrowheads) between adjacent cells forming a barrier
between the outer cerebrospinal fluid (o-CSF) in the subarachnoid space (SAS) and more superficial dural layers
(dural border cells (DBC) and the dura mater). Blood vessels (BV) in the SAS have tight junctions with similar barrier
characteristics as cerebral blood vessels without surrounding pericytes and astrocytic end-feet. Blood vessels within
the dura mater are fenestrated (f-BV). bm, basement membrane; gl, glia limitans. Redrawn from Saunders et al.
(2016b).
(iii) outer CSF–brain surface interfaces (Fig. 2F).
The outer CSF is the fluid-filled subarachnoid space.
Tight junctions are present between the cells of
the arachnoid barrier layer restricting permeability
between fenestrated blood vessels in the dura and
the subarachnoid space. The blood vessels within this
space have tight junctions between the endothelial
cells, but no astroctyic end feet or pericytes. This is
the interface that restricts exchange between the blood
and the outer CSF.
Molecular structure of tight junctions in brain barrier
interfaces
The molecular structure of tight junctions in brain
barrier interfaces has been extensively studied both in
vivo and in vitro. There are numerous proteins that
interact to form intercellular junctional structures in
many tissues including ZO-1, ZO-2, occludin and
several claudins. However, there is some degree of
specificity in the brain barriers. For example, in the
mammalian blood–brain barrier claudin 5 expression
is specific to this interface (Nitta et al. 2003; Kratzer
et al. 2012) although in zebrafish it is apparently also
expressed at the blood–CSF barrier (van Leewen et al.
2018). Angiogensis and blood–brain barrier formation
appear to be linked and occur simultaneously; by using
genetic mouse models, the effectors of Wnt/b-catenin
signaling, including Lef1, Apcdd1 and tnfrsf19, have
been shown to control these processes (reviewed in
Daneman & Prat, 2015). Recently it has been shown
that Reck (a glycosylphosphatidylinositol-anchored
membrane protein) and Gpr124, an orphan
G-protein-coupled receptor, promote both CNS
angiogenesis and blood–brain barrier formation by
activating the canonical Wnt7a/7b pathway (Cho et al.
2017).
Functional implications of the junctional structures of
brain barriers
It is important to stress that these interfaces are
functionally much more than a structural barrier pre-
venting passive exchange of molecules between the blood,
CSF and brain. Nevertheless this seal is important not
just because it prevents the intercellular passage of even
very small (lipid insoluble) molecules, but also because
this restriction allows the numerous cellular exchange
mechanisms to act in concert over the full extent of
the interface. For example without such a diffusion
restriction it would not be possible for the ion exchange
mechanisms to tightly control the ionic milieu of the
brain’s extracellular fluid that is essential for normal
neuronal function.
C© 2018 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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Figure 2. Morphology of the brain barriers illustrated in Fig. 1
Aa, the blood–brain barrier. Light micrograph showing the localization of biotin ethylenediamine (BED) in the
neocortex of opossum at P5 20–25 min after an intraperitoneal injection. Note that the staining for BED is most
visible within the vessels, in the marginal and subplate zones. cp, cortical plate; mz, marginal zone; sp, subplate.
Ab, localization of biotin–dextran (BDA3000) in the neocortex of P2 opossum 20–25 min after an intraperitoneal
injection. Arrowhead points to site of the tight junction. Note that themarker is prevented from passing through the
C© 2018 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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intercellular space by the tight junction. From Ek et al. (2006). B, the blood–CSF barrier. Lateral ventricular choroid
plexus (blood–CSF barrier) in P13 Monodelphis. Tight junction excludes entry of BDA3000 into CSF. Labelled
dextran present in one large and several smaller endosomes. From Ek et al. (2003). C, Circumventricular organs.
a, adjacent tanycytes facing the CSF in circumventricular organs are connected by an extensive network of apical
tight junctional strands shown here by freeze fracture of the adult Mongolian gerbil subcommissural organ. b, a
thin section electron micrograph of the same region in a neonatal animal shows multiple ‘kissing points’ (arrows)
between neighbouring tanycytes indicating a complete occlusion of the paracellular pathway. From Madsen &
Møllga˚rd (1979). D, ependyma in adult brain. Junctional configuration in the ependymal layer of 125-day sheep
fetus similar to those found in mature ependyma. ZA, zonulae adherens. Note unobstructed intercellular space. E,
the embryonic CSF–brain barrier. a, thin-section electron micrograph of the neuroepithelial lining of the cerebral
vesicle from an E19 sheep. The junctional zone exhibits very narrow intercellular clefts which at places seem to be
totally occluded (arrows). This junctional configuration has been named ‘strap’ junction. b, characteristic freeze
fracture single strand of strap junction perpendicular to CSF surface. From Møllga˚rd et al. (1987). F, the meningeal
barrier. Distribution of claudin-11 immunoreactivity in sagittal sections of E18 rat (a and b) and 21st wpc human
(c) brain. Demonstrates a strong reactivity of the entire arachnoid barrier cell layer = arachnoid blood–CSF barrier
(aB-CSFB, arrowheads). From Brøchner et al. (2015). CM, cisterna magna; EFL, radial glial end feet layer; SAS,
subarachnoid space; TC, tentorium cerebelli.
Alternative route into the brain
There have also been suggestions of ‘another route’ of
entry into the very early embryonic brain before most
of the characteristics of the six barrier interfaces have
appeared. Bueno and colleagues have carried out extensive
studies of the properties of CSF in chick embryos (eCSF)
before the appearance of the choroid plexuses. They have
also studied the transfer of proteins and other molecules
between the blood andneural tube tissue (Parvas&Bueno,
2010; Bueno et al. 2014). Their evidence suggests that the
internal environment of the CNS at this very early stage of
development is alreadywell controlled. The route of trans-
fer appears to be in the brainstem lateral to the floor plate,
in the ventral mesencephalon and in the most anterior
part of the ventral prosencephalon. This location does
not correspond to the site at which the choroid plexus
later develops. From studies of zebrafish embryos, Lowery
& Sive (2009) suggest that eCSF is a secretion of the
neuroepithelium forming the neural tube. However, the
studies of Bueno and colleagues demonstrate clearly that
the composition of eCSF in the chick embryo depends
importantly on transfer from the blood into eCSF (Parvas
& Bueno, 2010; Bueno et al. 2014).
Lehtinen and colleagues (Zappaterra et al. 2007;
Chau et al. 2015) have carried out extensive studies
of the composition of amniotic fluid and eCSF
in the period after neural tube closure (described
below in the section ‘Proteins in fetal and newborn
CSF’).
Physiological and molecular evidence for effective
barrier mechanisms in the developing brain
Evidence for early establishment of ion gradients
between CSF and plasma. The identificationof a gradient
between CSF and plasma for even a single ion implies
that at least two essential features of a barrier mechanism
are present: (i) tight junctions between the cells of the
interface that are functionally effective in enabling the
gradient to be established, and (ii) a cellular pump
that sets up the gradient. This is amongst the most
convincing evidence for functional barrier mechanisms
in the developing brain. The ionic composition of
CSF is thought to reflect that of the general inter-
nal environment of the developing brain, although
there is some controversy about the extent to which
CSF composition actually reflects blood–brain barrier
properties; this is important for correct interpretation of
CSF data in clinical conditions in adult patients (Lange,
2013) but does not seem to be used in neonates (see
below). There have been numerous studies in a variety
of species showing the presence of ion gradients between
CSF and plasma, some from very early in development,
as summarized in Table 1 and illustrated for the rat in
Fig. 3.
A significant consideration in interpreting these results
is that some ions (Ca2+ and Mg2+) bind to proteins in
plasma and CSF, particularly to albumin, and the protein
concentration in fetal CSF is much higher at a time when
it is lower in plasma (see below). Protein concentrations
in CSF and plasma are important because they affect
the proportion of each fluid that the electrolytes are
dispersed in. Thus accurate comparisons between electro-
lyte concentrations in the two fluids can only be made
when the units take account of this (mEq kg−1 H2O).
As can be seen in Table 1, most estimates have used
units based on volume of CSF or plasma (which includes
protein) and thus need to be interpreted with caution.
Nevertheless it is clear from Table 1 that concentration
gradients are established early in brain development.
No values appear to be available for human embryos
or fetuses; values for neonates and infant are rare. No
reference values are given in textbooks of fetal and
neonatal medicine and CSF electrolytes do not appear
to be routinely measured in neonates (Royal Children’s
Hospital Melbourne; Royal Children’s Hospital, Brisbane;
Prof. R. Ariagno, Neonatologist, Stanford University).
C© 2018 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
5730 N. R. Saunders and others J Physiol 596.23
Table 1. Electrolyte concentration (mmol L−1 or mEq kg−1 H2O) in CSF and plasma of embryos/newborns and adults
Species Age Units Fluid Na+ K+ Cl− HCO3− Ca2+ Mg2+ Ref
Monkey, term 168 days E50–60 mEq kg−1 H2O CSF 3.6 3.8 1.85 1
Plasma 4.1 4.9 1.5 1
E90 mEq kg−1 H2O CSF 3.2 3.5 2.3 1
Plasma 4.0 5.0 1.5 1
E130 mEq kg−1 H2O CSF 2.9 2.9 2.2 1
Plasma 3.8 4.9 1.5 1
Adult mEq kg−1 H2O CSF 2.6 2.3 1.9 1
Plasma 4.5 4.6 1.2 1
Rabbit, term 31 days E23 mEq L−1 CSF 142 4.1 113 1.5 2
Plasma 143 6.5 104 3.2 2
E27 mEq L−1 CSF 140 4.0 110 1.6 2
Plasma 147 6.0 108 3.6 2
Adult mEq L−1 CSF 150 3.0 120 1.4 2
Plasma 154 3.2 100 2.2 2
Rat, term 21 days P0 mEq L−1 CSF 144 3.8 109 2
Plasma 150 6.5 102 2
P8 mEq L−1 CSF 144 3.8 107 2
Plasma 166 7.1 98 2
Adult mEq L−1 CSF 152 3.0 122 2
Plasma 153 5.0 106 2
Sheep, term 150 days E44–50 mEq L−1 CSF 135 5.4 113 — 2.0 3
Plasma 138 — 113 — 1.6 3
E85–92 mEq L−1 CSF 144 3.5 123 3.4 1.9 3
Plasma 136 3.8 104 6.05 1.8 3
Adult mEq L−1 CSF 148 3.1 128 2.45 1.8 3
Plasma 138 3.4 115 3.4 1.4 3
Pig, term 115 days 5 cm CRL mmol L−1 H2O CSF 126 115 4
Plasma† 125 112 4
6.5 cm CRL mmol L−1 H2O CSF 120 115 4
Plasma† 110 98 4
12.5 cm CRL mmol L−1 H2O CSF 125 122 4
Plasma† 105 96 4
Pony, term 342 days E312 mmol L−1 CSF 143 3.7 109 5
Serum 134 5.7 5
E342 mmol L−1 CSF 143 2.9 112 5
Serum∗ — — — 5
Adult mmol L−1 CSF 144 2.9 101 5
Serum 132 4.7 94 5
Chick, hatch 20–21 days E13 mEq L−1 CSF 121 3.9 104 6
Plasma 117 6.3 101 6
E15 mEq L−1 CSF 125 3.6 103 6
Plasma 120 5.8 91 6
E19 mEq L−1 CSF 129 3.8 109 6
Plasma 134 7.8 93 6
Adult mmol kg−1 H2O CSF 159 4.2 142 7
Plasma 160 4.7 115 7
(Continued)
This misses the possibility of using ion gradients between
CSF and plasma as a means of assessing choroid plexus
and blood–brain barrier function in human neonates,
as suggested many years ago by Bito & Myers (1970):
‘Existence of normal cation concentration gradients
between CSF and blood may serve as a criterion for the
normality of the (foetal) blood–brain barrier’.
More recently transcriptomic studies have shown that
key ion channel and transporter genes are expressed
very early in embryonic life in the choroid plexuses
(Liddelow et al. 2012, 2013). These are summarized in
Fig. 4. One puzzle is the astonishing number of some
channel genes that are expressed in development when
we have no idea whether they are functionally effective.
C© 2018 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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Table 1. Continued
Species Age Units Fluid Na+ K+ Cl− HCO3− Ca2+ Mg2+ Ref
Human, 38 weeks’
post–conception
P0–4 weeks mmol L−1 CSF 138 3.2 117 1.6 8
Plasma 136 5.4 105 2.3 8
P7–12 months mmol L−1 CSF 142 2.5 120 1.4 8
Plasma 136 4.9 107 2.7 8
P7–14 years mm L−1 CSF 141 2.8 122 1.3 8
Plasma 138 4.6 107 2.7 8
Adult mEq kg−1 H2O CSF 147 2.9 113 23 2.3 2.2 9
Plasma 150 4.6 99 27 4.7 1.6 9
References: (1) Bito & Myers (1970), cisternal CSF; (2) Amtorp & Sorensen (1974), cisternal CSF; (3) Bradbury et al. (1972), cisternal CSF;
(4) Flexner (1938), cisternal CSF; (5) Rossdale et al. (1982), atlanto-occipital subarachnoid CSF; (6) Stastny & Rychter (1976), ventricular
CSF; (7) Anderson & Hazelwood (1969), cisternal CSF; (8) Heine et al. (1981), lumbar CSF; (9) Davson & Segal (1996), lumbar CSF. Note
differences in units. The most appropriate are mmol L−1 or mEq kg−1 H2O as this allows for differences in protein concentration in
CSF and plasma (see Davson, 1967, for discussion). These are markedly different early in development, as well as between CSF and
plasma, see section on ‘Proteins in CSF’. ∗Not measured; †calculated from CSF/plasma ratios. CRL, crown rump length.
Many of these channels are expressed at a higher level
in the developing rat choroid plexus than in the adult.
Numerous gene family members for K+ voltage gated
channels were expressed at levels of between 2- and
210-fold higher in E15 choroid plexus than adult. Seven
Scn genes (voltage gated sodium channels), nine Trpv
channels, two chloride channel genes (Clic1, Clic4) and
two cyclic nucleotide gated channels (Cnga1 and Cnga3)
were also expressed at a higher level in the developing
choroid plexus. In addition there were six ion channel
genes that were expressed only at E15 (Kcnmb2, Tmc5,
Clcnka, Scnn1g, Kcnh8, Kcnmb1) and one in the adult
(Kcnk9). Thirteen genes of the Cacn family of voltage
gated Ca2+ subunits were expressed at higher levels in
E15 choroid plexus than in the adult (Liddelow et al.
2013).
Newborn
Newborn
Adult
Adult
Adult
Na+
K+ Ca2+
CI– HCO3
– H2O
150 6.5 2.5 102 25.5
153 5.0 2.9 105 20.5
48 145 – 65 9.5
152 3.2 1.4 125 25.8
144 3.9 2.4 108 24.3
CSF
Blood
Figure 3. Ion gradients between CSF and plasma in developing and adult rat brain
A characteristic of CSF is its stable ionic composition that differs from that of plasma to an extent that cannot be
explained by ultrafiltration, as was once thought. Data for CSF and plasma (mEq L−1 H2O) are from Amtorp &
Sørensen (1974) and for intracellular ions (mmol L−1 H2O) from Fig. 8 in Johanson & Murphy (1990). The gradients
are the consequence of the complex interactions between enzymes (notably carbonic anhydrase) ion transporters
and ion channels, as illustrated in Fig. 4. The CSF secretion rate in the embryo and newborn is much lower than in
the adult (Bass & Lundborg, 1973; Johanson & Woodbury, 1974), which is perhaps explained by the much lower
expression of carbonic anhydrase and ATPases in the developing choroid plexus, as indicated in Fig. 4. Redrawn
from Saunders et al. (2016b).
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Influx mechanisms. Themain functional groups of influx
transporters in brain barrier interfaces defined from
physiological studies are those for glucose (GLUT-1),
amino acids (acidic, basic, neutral) monocarboxylic acids,
peptides and ions, including metabolically important
ions such as Fe2+, Cu2+ and Mg+. These mechanisms
are summarized in Fig. 5. Most of the physiological
studies were published many years ago, but this does not
diminish their value in understanding the importance
of such mechanisms in the developing brain. There is a
fundamental difficulty in designing adequate experiments
to study the mechanisms that control the influx of these
molecules and ions into the brain and CSF because it is
important, but technically difficult, to distinguish between
transport andmetabolic incorporation intodifferent brain
compartments and structures. This problem was solved
Name
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Car1 (CAR1)
Car8 (CAR8)
Clic1 (CLIC1)
Clic4 (CLIC4)
Kcnj12 (Kir2.2)
Kcnj3 (Kir3.1)
Kcnj8 (Kir6.1)
Kcna3 (Kv1.3)
Kcna5 (Kvi.5)
Kcna6 (Kv1.6)
Slc4a1 (AE1)
FD
E15 only
5.4
77.0
2.4
6.4
17.0
13.0
14.0
14.0
14.0
14.0
59.0
Name
Slc4a3 (AE3)
Slc4a4 (NBC1)
Slc9a5 (NHE5)
FD
2.7
3.9
7.1
Name
Slc9a1 (NHE1)
Scl12a6 (KCC3)
FD
1.9
1.5
EMBRYO ENRICHED
ENRICHED BOTH AGES
Name
Atpb1 (ATPB1*)
Aqp1 (AQP1)
Aqp4 (AQP4)
Car12 (CAR12)
Car2 (CAR2)
Clic2 (CLIC2)
Clic3 (CLIC3)
Clic5 (CLIC5)
Clic6 (CLIC6)
Clcnkb (CICKb)
Kcna1 (Kv1.1)
Kcnj13 (KIR7.1)
FD
72.0
2.8
20.0
18.0
9.0
6.2
7.2
9.8
2.9
8.2
164.0
11.0
Name
Slc12a2 (NKCC1)
Slc12a3 (NCCT)
Slc12a4 (KCC1)
Slc4a2 (AE2)
Slc4a5 (NBCe2)
Slc4a10 (NBCn2)
FD
7.4
7.5
3.1
3.3
5.4
61.0
ADULT ENRICHED
CI–
CI–
CI– CI–
CI– CI–
2CI– 3HCO3
–
HCO3
–
HCO3
– HCO3
–
HCO3
–
2HCO3
–
CO2CO2
H+
H+
H+
K+
K+ K+ K+ K+ H2O
H2O
H2O
H2O
K+ K+
2K+
3Na+ Na+
Na+
Na+
Na+
Na+Na+ 2CI–Na+
CAR1 CAR12
CLIC1
CLIC4
CLIC2
CLIC3
CLIC5
CLIC6
TJ
CICKb NHE5 NHE1 ATPB1 NKCC1 NBCe2 Kv1.1 Kv7.1 AQP3
AQP1
AQP4
Kv1.3
Kv1.5
Kv1.6
Kir2.2
Kir3.1
Kir6.1
AE2 NBC1 NBCn2 NCCTKCC1 KCC3 AQP1
AE1
AE3
CAR8 CAR2
CSF
Blood
Figure 4. Localization of proteins for ion transporters, channels and associated enzymes and
identification of their corresponding genes in adult and immature rat choroid plexus
CSF secretion results from coordinated intracellular carbonic anhydrase activity and transport of ions and water
from basolateral membrane to cytoplasm, then sequentially across apical membrane into the cerebral ventricles
(Davson & Segal, 1996; Speake et al. 2001; Praetorius & Damkier, 2017). This process has only been studied in
adult choroid plexus (Brown et al. 2004; Praetorius & Damkier, 2017). The membrane and intracellular locations of
the ion channels, transporters and enzymes indicated are from Praetorius & Damkier (2017). Data from Liddelow
et al. (2013) compares expression of these genes and other functionally related genes in E15 and adult rat lateral
ventricular choroid plexus. Blue indicates the genes that are upregulated (enriched) in the adult. Light red indicates
genes that are expressed at a higher level at E15. We have assumed the same cellular/membrane location for
members of the same gene family. The genes all had substantial but variable transcript numbers in the RNA-Seq
analysis. In some cases where a gene was upregulated in the adult, the transcript number was also high in the
embryo, suggesting this transporter or channel was likely to be functionally effective at both ages, e.g. the K+
channel Kcnj13 (Kir7.1), Slc12a2 (NKCC1) a Na+–K+–Cl− exchanger and Slc4a2 (NBCe2) a coupled Na+–HCO3−
pump. ATPB1 (Atpb1b1) is a Na+/K+-ATPase. Green indicates genes that were expressed at similar levels at the two
ages. There are many more channels that show age-related differential expression in choroid plexus, the functions
of which are unclear. Redrawn from Liddelow et al. (2016) with additional data from Liddelow et al. (2013).
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by Oldendorf (1971) with the introduction of a short
pass technique initially for studies in adult animals.
Although technically more difficult, it has also been
applied to a limited extent and with some modifications
in developing animals (Braun et al. 1980; Cornford et al.
1982; Lefauconnier & Trouve´, 1983). The essence of the
technique is that a radiolabelled compound is injected
as close as possible to the cerebral circulation and the
experiment is rapidly terminated after enough time for
only one circuit through the cerebral circulation. Usually
two labelled compounds are compared: one, which would
be expected to enter almost instantaneously, as a reference
(e.g. 3HOH), and a second that is the compound of inter-
est, usually an amino acid or glucose. For those interested,
we have reviewed these physiological experiments pre-
viously (Saunders et al. 2012, 2013).
Amino acids. It seems to have been assumed in most
studies that entry into the brain was via the blood–brain
barrier interface only and account was probably not
taken of any entry via the choroid plexuses into the CSF.
More importantly, in most studies it was not clear if the
CSF and choroid plexuses had been removed prior to
analysis of brain samples; any choroid plexus tissue or
CSF included in the brain samples would have led to an
overestimate of the contribution of blood–brain barrier
transport of the amino acids into the brain, because at
least some amino acids accumulate in the choroid plexuses
(al-Sarraf et al. 1997a) in addition to entering the CSF
directly. There seems to have been only one series of
studies of direct entry into CSF in the developing brain,
whichwouldmainly reflect entry across theblood–choroid
plexus barrier (al-Sarraf et al. 1995, 1997b). The results
showed greater entry of some amino acids into neonatal
rat CSF than that of the adult and in some cases the entry
into CSF was greater than into the brain; thus entry via
the choroid plexus appears to be more important than
across cerebral blood vessels at this early stage of brain
development. The higher entry is presumably a reflection
of the metabolic requirements of a rapidly growing brain,
although some have interpreted it as due to ‘immaturity’
of the blood–brain barrier (e.g. Watson et al. 2006). There
is only a small amount of information about amino acids
in CSF in children, but this indicates that the CSF/plasma
concentration ratios are higher in 0- to 3-year-old children
than in older children for some amino acids (serine, valine,
histidine and arginine, but lower for glutamate, Akiyama
et al. 2014). Scholl-Burgi et al. (2008) and Jime´nez et al.
(2012) have published values for CSF and plasma amino
acids in the first year of human life; they confirm that
several amino acids are present in neonatal CSF at higher
levels than later in life and with higher CSF/plasma ratios.
This is consistent with the animal data showing higher
transport early in brain development and is presumably a
Glucose
Glucose
Amino
acids
Ala, Cys,
His, Pro,
Met, Trp
Nucleosides
Nucleotides
Adenine
adenosine
Receptor
mediated
Transferrin
insulin
leptin
Mono-
carboxylates
Lactate
ketones
Others
Na+, K+
other ions
MeHg
(Cys) Glu
Pb2+
(Cys)
Zn2+
(His) Mn2+ Fe2+
MCT1
MCT8
GLUT1
Brain
Blood
Figure 5. Influx transporters at the blood–brain barrier
These are mainly SLC (solute carrier) transporters. See Hediger (2013) for comprehensive review. Only transporters
for which there is physiological evidence for function are listed. As indicated in Table 2, transcripts for many more
Slcs have been identified in molecular screens. Many of these genes are found in both endothelial cells of the
blood–brain barrier and epithelial cells of the choroid plexuses. Others are unique to each interface as summarized
in Table 2. Note, many metal ions that are potentially toxic can be carried in via some of these transporters.
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reflection of metabolic requirements at a time when the
brain is still growing rapidly.
There is now substantial information about gene
expression in the blood vessels and choroid plexus of
the developing brain. These data are summarized for Slc
(solute carrier) transporters in developing mouse brain in
Table 2. There is a strikingly large number of Slc transcripts
in almost all families that have been identified in cerebral
endothelial cells, choroid plexus epithelial cells or both.
There thus appears tobe a large amountof redundancy and
which precise Slcs are responsible for specific amino acid
or othermolecules is unclear. However, there are instances
where a mutation in a single Slc gene has serious effects on
brain development; for example inmice deletion of Slc7a5,
a large neutral amino acid transporter, leads to severe
neurological abnormalities. In a few patients deleterious
homozygous mutations of this gene were associated with
motor delay and autistic traits (Tarlungeanu et al. 2016).
When many Slcs are involved in transport of the same
amino acids it is difficult to assign specific Slcs to each
amino acid class. In Table 3 we indicate Slc genes that may
correspond to the transporters for molecules where there
is evidence of their entry from blood into the developing
brain, but many others may also be involved.
Monocarboxylates. A family of monocarboxylate trans-
porters (MCTs) is involved in transport of mono-
carboxylates (e.g. pyruvate, lactate and ketone bodies)
across plasma membranes, some of which are proton
linked. These are now designated as members of the
SLC16 family, of which there are 14 (Halestrup, 2013a).
Thus far only four have been shown to be involved
in monocarboxylate transport in humans (Halestrap,
2013b): SLC16A1 (MCT1), SLC16A3 (MCT4), SLC16A7
(MCT2) and SLC16A8 (MCT3). SLC16A1 (MCT1) is
involved in transport of monocarboxylates across the
endothelial cells of the blood–brain barrier (Halestrup,
2013a,b). Slc16a1 (MCT1), a2 (MCT8), a6 (MCT7), a8
(MCT3), a9 (MCT9), a12 (MCT12) and a13 (MCT13)
genes have been identified in adult mouse choroid plexus
(Koehler-Stec et al. 1998; Marques et al. 2011; Saunders
et al. 2015a). Slc16a2 is a thyroid hormone transporter,
which is expressed at similar levels in embryonic and adult
choroid plexus; the others are all monocarboxylate trans-
porters and expressed at a lower level in the rat embryonic
plexus compared to the adult (Saunders et al. 2015a).
Only Slc16a10 (MCT10) is expressed at a higher level
in mouse and rat embryonic choroid plexus compared
to adult (Liddelow et al. 2012; Saunders et al. 2015a).
Slc16a10 transports tyrosine, the amino acid precursor of
the thyroid hormones tri- and tetraiodothyronine. The
protein product of Slc16a10 has been shown to have much
stronger immunohistochemical staining in embryonic
compared to adult choroid plexus (Saunders et al. 2015a).
This suggests that the very high expression of this trans-
porter reflects an important role in thyroid hormone
transport in early brain development.
Triiodothyronine (T3) and thyroxine (T4) are essential
for normal brain development. Inadequate delivery of T4
to the developing brain is usually due to iodine deficiency;
it may result in cretinism (Rivas & Naranjo, 2007; Skeaff,
2011). The choroid plexuses in the embryonic brain are
prominent compared to vascularization of the rest of the
brain and it has been suggested to be the main portal of
entry into thedevelopingbrain (Johansson et al.2008); this
is consistent with high expression of Slc16a10 (MCT10)
in the choroid plexuses early in development. Trans-
thyretin (TTR) a thyroidhormone carrier highly expressed
throughout development, is the major mechanism pre-
viously thought to deliver thyroxine to the brain in
early stages of its development, whereas Slco1c1, which
is the main thyroid hormone transporter expressed at
the blood–brain interfaces in the adult, is expressed
at only a low level in the developing brain (Kratzer
et al. 2013). Notwithstanding that Slc16a2 (MCT8) is
expressed at similar levels in the developing and adult
brain (in rodents), in humans mutations of this gene
cause an X-linked syndrome of psychomotor retardation
and altered thyroid hormone levels (Lo´pez-Espı´ndola
et al. 2014). Thus this gene is critical for normal human
brain development. It seems not to be known what the
expression level of Slc16a10 (MCT10) is in the human
fetus nor have mutations been reported. Slc16a2 (MCT8)
appears not to be critical for rodent brain development, as
there is no neurological phenotype in knock-out animals
(Visser, 2016). Thus there appear to be species differences
in the relative importance of thyroid hormone trans-
porters for brain development.
Glucose. GLUT-1 (SLC2a1, solute-linked carrier, SLC
transporters) was the first glucose transporter to be
described; its gene, Slc2a1, is expressed in both cerebral
endothelial cells (Daneman et al. 2010a) and choroid
plexus epithelial cells (Liddelow et al.2012, 2013).GLUT-1
is a facilitative transporter. It is the main member of this
family in cerebral endothelial cells (Enerson & Drewes,
2006). Slc2a3, a8, a12 and a13 expression has also been
identified in mouse cerebral endothelial cells (Table 2).
Slc2a1 is expressed in rodent choroid plexus (Table 2);
in the embryo it is expressed at a slightly higher level
(Liddelow et al. 2013). Of the other glucose-transporting
genes in this family that have been identified in rat choroid
plexus (Slc2a3, a4, a8, a12, a13 and a15, see Table 2) only
Slc2a12 is expressed at a level that is likely tobe functionally
significant (at five times higher in the adult, Liddelow et al.
2013).
As summarized in Table 2, the SLC5 transporters are
sodium–glucose co-transporters. Slc5a1, a5 and a6 have
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Table 3. Comparison of Slc transporter gene expression and function in embryonic mouse (E15) choroid plexus and embryonic mouse
(E17) neuroepithelium
Transporter E15–adult
mouse CP
fold
change
E17–adult
mouse VZ
fold
change
Transport function Reference
Slc16a10 66.8 1.2 Iodothyronines T3, T4 Porterfield & Hendrich
(1992)
Slc16a2 n.d. −2.4 Monocarboxylates
Slc6a15 11.4 −2.7 Neutral amino acids Lefauconnier & Trouve´
(1983)
Slc40a1∗ 9.6 1.1 Fe2+ Morgan & Moos (2002)
Slc7a11 7.1 5.1 Cysteine, glutamate Lefauconnier & Trouve´
(1983)
Slc4a1 5.5 n.d. Anion transporter
(Cl−/HCO3− exchange)
Amtorp & Sørensen
(1974), Damkier et al.
(2010)
Slc6a13 4.6 2.4 GABA transporter Al-Sarraf (2002)
Slc1a4 4.4 −1.6 Glutamate, neutral
amino acids
Al-Sarraf et al. (1997a)
Slc38a4 4.2 0.94 Acidic and neutral
amino acids
Lefauconnier & Trouve´
(1983)
Al-Sarraf et al. (1997b)
Slc6a6 4.1 0.90 Taurine Lefauconnier & Trouve´
(1983)
Slc4a4 4.1 0.22 Na+–HCO3−
cotransporter
Damkier et al. (2010)
Slc7a1 4.1 1.99 Acidic amino acids Lefauconnier & Trouve´
(1983)
Slc39a8 3.3 2.63 Zn2+ Chowanadisai et al.
(2005)
Slc39a10 2.8 n.d. Zn2+ Chowanadisai et al.
(2005)
Slc25a37 2.4 5.5 Fe2+ Morgan & Moos (2002)
Slc14a2 2.4 n.d. Urea Johanson & Woodbury
(1978)
Slc7a7 2.3 n.d. Dibasic and neutral
amino acids
Lefauconnier & Trouve´
(1983)
Slc39a11 2.3 n.d. Zn2+ Chowanadisai et al.
(2005)
Slc43a2 2.2 3.9 Large neutral amino
acids
Oldendorf (1973)
Slc1a3 2.2 3.1 Glutamate Al-Sarraf et al. (1997a)
Transcript fold change ratios compared to adult. References are for evidence of transport (blood to brain or CSF) in physiological
experiments. Because of the large number of genes often involved in transport of similar classes of molecules, this is only an indication
that genes located at these sites are functional. Data from Liddelow et al. (2012) and Whish et al. (2015). There are many more Slc
genes that are expressed at a higher level in adult than in embryo, not listed here. ∗Gene product ferroportin-1 identified in choroid
plexus. n.d., not detected.
been identified in mouse cerebral endothelial cells and
Slc5a6 and Slc5a10 are present in mouse choroid plexus.
There is good evidence from physiological experiments
for glucose transport into the brain in both adult and
neonatal rats and rabbits (Oldendorf, 1971; Cornford et al.
1982; Cornford & Cornford, 1986; Vannucci et al. 1994).
Much of this is probably mediated by GLUT-1 (SLC2a1).
As indicated abovewith respect to amino acid transporters
there is a general problem, yet to be resolved, where many
transporters for the same substrate have evolved; there are
currently nomethods available for unequivocally linking a
specific transporter to a specific contribution to transport.
However, it is clear that at least in the case of GLUT-1
this apparent redundancy does not compensate for the
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loss of GLUT-1 function (Ito et al. 2015). So perhaps
the redundancy is there to entertain molecular biologists
rather than having particular biological relevance.
A comprehensive study of gene expression profiles
in embryonic mouse brain in bulk tissue samples and
separated endothelial cells has recently been published
(Hupe et al. 2017). Unfortunately its value is limited
because the authors do not appear to have ex-
cluded choroid plexuses from their tissue samples and
the method used to separate endothelial cells would have
also included those from the choroid plexuses; these are
considerably more vascularized in embryonic brain than
is the brain itself (Johansson et al. 2008).
Efflux mechanisms protecting the developing brain
The developing brain is protected by a combination of
morphological features and cellular effluxmechanisms, as
is the adult brain. An important practical and biological
question is to what extent these are functional in the
embryo, fetus and newborn. In particular how vulnerable
is the developing brain to drugs and toxins reaching it
from the mother across the placenta or via the milk? This
will be the subject of a review to be published later in
2018 (Saunders et al., Annual Review of Pharmacology and
Toxicology); this aspect of brain barrier mechanisms will
only be dealt with in outline here.
The main mechanisms that remove or exclude
metabolic and potentially toxic compounds such as drugs
across brain barriers in the adult brain are ATP-binding
cassette (ABC) efflux transporters (Hartz & Bauer 2011)
and some of the Slc families of transporters: Slc21
now re-designated as Slco1 (solute carrier organic anion
transporter), Slc15 and Slc22 (Strazielle & Ghersi-Egea,
2015). The main efflux transporters at the adult
blood–brain barrier are illustrated in Fig. 6. These are:
ABCB1 (P-glycoprotein or MDR1) and ABCG2 (breast
cancer resistance protein; BCRP). ABCC2 (multidrug
resistance-associated protein 2; MRP2), ABCC4 (MRP4)
have also been demonstrated at the blood–brain barrier
interface (Strazielle & Ghersi-Egea, 2015). In cerebral
capillary endothelial cells they export compounds into
the blood. At the blood–CSF interface ABCC1 (multidrug
resistance-associated protein 1; MRP1) is the main efflux
transporter, but ABCC4 (MRP4) and ABCG2 (BCRP) are
also present (Ek et al. 2010; Strazielle & Ghersi-Egea,
2015). They export compounds into the stroma of the
plexus (Maliepaard et al. 2001; Ek et al. 2010). BCRP and
MRP transport compounds that have been conjugated
to specific transport motifs (glutathione, glucuronic acid
or sulphated), which confer a wide range of substrate
specificity and considerable overlap between transporters
(see Fig. 6 and Lo¨scher & Potschka, 2005). There are
probably species differences in the level of expression
and functional capacity of these various efflux trans-
porters. From limited studies of the developing brain
it seems that expression changes with age during brain
development at both interfaces (Schumacher &Møllga˚rd,
1997; Virgintino et al. 2008; Ek et al. 2010; Daneman
et al. 2010b; Kratzer et al. 2013); however, there are few
functional studies dealing with the problem of whether
these transporters are functionally effective. Even less
is known about the presence of ABC transporters in
brain barriers of the human embryo and fetus. We have
published an immunohistochemical study of three of these
transporters (P-glycoprotein, BCRP and MRP1) from
5weeks’ post-conception tomid-gestation (Møllga˚rd et al.
2017) that reveals some striking differences between these
transporters. Thus P-glycoprotein was not detectable at
any barrier interface at 5 weeks’ post-conception (but was
detectable later in gestation), whereas the other two were
detectable from the earliest ages but with differences in
their distribution patterns (Møllga˚rd et al. 2017).
The Slc22 gene family of efflux transporters includes
organic anion and cation transporters (OAT, OCT and
OCTN proteins). Slco (SLC21) is a subfamily of organic
anion transporting polypeptides (OATPs). The homology
between rodent and human Slco genes is inexact. Judging
from their cellular localization some may function
as influx rather than efflux transporters (Strazielle &
Ghersi-Egea, 2015). In rat choroid plexus most Slco and
efflux Slc genes are expressed at similar or higher levels
• Sulphate
• Glutathione
• Glutathione
• Glucuronic acid
• Sulphate
ATP
ADP
ATP
ADP
ATP
ADP
ATP
ADP
Brain
Blood
PGP BCRP MRP Others
Figure 6. Efflux transporters at the blood–brain barrier
These are mainly ATP-binding cassette (ABC) transporters. Some,
e.g. P-glycoprotein (PGP; ABCB1), reduce entry into cells. Others,
e.g. multidrug resistance protein (MRPs; ABCCs), ligand (drug or
toxin) combines with glutathione, glucuronic acid or sulphate in cells
before efflux. BCRP, breast cancer resistance protein (ABCG2).
‘Others’ include SLC efflux (SLCO) transporters.
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than in the adult, except for Slc22a8, which is expressed at
a lower level in the embryo and neonate. Slc15a2 is well
expressed in both brain and choroid plexus at similar levels
indeveloping andadult choroidplexus.Comparisonof the
developmental profiles ofABCandSLCefflux transporters
in rats shows the adult pattern is achieved earlier in the
choroid plexus than in the blood–brain barrier (Strazielle
& Ghersi-Egea, 2015). Nothing seems to be known about
the expression or presence of SLC efflux transporters in
the human fetal brain.
The extent to which gene or protein expression of
an ABC transporter in the developing human brain
corresponds to function in vivo cannot be determined
experimentally. Thus animal studies are required, but very
few studies of drug entry related to efflux transporter
function in the developing brain have been performed;
notable exceptions are the papers of Staud and colleagues
(Staud et al. 2006; Cygalova et al. 2008). Knowledge of
the presence and effectiveness of efflux transporters in
the developing brain is essential for assessing the risk
to fetuses when drugs are administered to a mother.
Systematic understanding of efflux transporter expression
and function would allow a rational approach to safer
prescription of drugs in pregnant women.
Proteins in fetal and newborn CSF
Theprotein concentration in fetalCSF ismuchhigher than
in the adult (Dziegielewska & Saunders, 1988; Saunders
et al. 1999). The first quantitative estimates of protein
concentration in CSF of embryos appear to be those of
Klosovski (1963) in embryonic and postnatal cats.He used
an uncalibrated spectrophotometricmethod and reported
that the protein concentration in 10 cm (E48, term is
E63–70, Evans & Sack, 1973) embryos was 21.6 times
higher than in the adult. Wahle et al. (2014) recorded a
median value of 10 mg (100 mL)−1 for adult cat, which
if assumed for Klosovski’s data gives 216 mg (100 mL)−1
at a post-conception age of about 60 days (cf. Fig. 7).
This is somewhat below the values for sheep and pig
fetuses at this age but much higher than species with
smaller brains (Fig. 7). It has been suggested that a
possible function of the high concentration of protein
in CSF of the developing brain is to provide an oncotic
pressure gradient, which expands the ventricular system
(Saunders, 1992). Deflation of the ventricular system
in the chick embryo resulted in very abnormal brain
development (Desmond & Jacobsen, 1977). Thus a higher
concentration of protein in the ventricular systemof larger
brains may be a component of the mechanisms required
for achieving the larger brain, which essentially grows
around the expanding ventricles. The presence of strap
junctions between cells of the neuroepithelium that line
the ventricular system are also likely to be an important
structural component of this mechanism. They have been
shown to be impermeable to proteins and other large
molecules early in brain development (Fossan et al. 1985;
Whish et al. 2015). Without such a diffusion impediment,
the oncotic pressure generated by proteins in CSF would
be ineffective. The peak in CSF protein in the various
species studied (Fig. 7) coincides with the time when
the developing brain is generating the neurons that form
the cortical plate, the forerunner of the neocortical layers
that form the neocortex (see Table 1 in Dziegielewska
et al. 2000). The diffusion restriction provided by the
strap junctions of the neuroepithelium may provide
an important mechanism for regulation of the local
environment to which the cells of the neuroepithelium are
exposed.
The protein composition of CSF in the developing
brains has been reported for a number of species (reviewed
in Dziegielewska & Saunders, 1988). These studies used
immunological methods to characterize and quantify
major proteins in CSF from developing brains. More
recently proteomic studies of the composition of CSF at
very early stages of brain development, including before
the differentiation of the choroid plexuses, have been
published (chick and rat embryos, Parada et al. 2005;
rat and human embryos, Zappaterra et al. 2007). These
comprehensive methods identified many more proteins
in CSF from developing brain in these species. In a
1,000
500
0
0 40 80 120 160
Age (days after conception)
C
S
F
 p
ro
te
in
 c
on
c.
 (
m
g/
10
0m
l)
wallaby
sheep
pig
ch
ic
ke
n
rabbit
rat
opossum
Figure 7. Total protein concentration in CSF of various species
at different post-conceptional ages
Ordinate: total protein concentration mg (100 mL CSF)−1. Abscissa:
post-conceptional age in days. Filled circles indicate time of birth.
Data for sheep from Dziegielewska et al. (1980a); pig (Cavanagh
et al. 1982); rat (Dziegielewska et al. 1981; Checiu et al. 1984);
tammar wallaby, Macropus eugenii (Dziegielewska et al. 1986);
opossum, Monodelphis domestica (Dziegielewska et al. 1989); chick,
(Birge et al. 1974); rabbit (Ramey & Birge (1979). Adult values not
shown. For mammalian species, including human (see Davson,
1967) and marsupials mean values are between 23 and
31 mg (100 mL)−1. Chicken is 141 mg (100 mL)−1.
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comparison of amniotic fluid and early CSF from mouse
embryos, Chau et al. (2015) showed that amniotic fluid
at E8.5, the time of neural tube closure, contained many
more proteins (764) than eCSF at E10.5 (504) or E14.5
(410). In the initial stages of development after neural tube
closure there is a decline in the total protein concentration
in eCSF, followed by an increase around the time of
differentiationof the choroidplexuses as previously shown
(Dziegielewska et al. 1981). These studies of eCSF coupled
with ones that begin to relate specific properties of CSF to
particular features of early brain development (e.g. Gato
& Desmond, 2009; Lehtinen & Walsh, 2011; Lehtinen
et al. 2011, 2013; Gato et al. 2014) are opening a new era
of understanding of blood–brain and blood–CSF barrier
properties and how they relate to brain development.
There is much less information about proteins in
human fetal CSF. Adinolfi and colleagues have published
some valuable data on this and have shown that as in
animal species the total protein concentration is very high
compared to the neonate and adult. Thus at 14 weeks’
gestation the CSF total protein concentration was about
120mg (100mL)−1 increasing to over 560mg (100mL)−1
at 20–24 weeks’ gestation (Adinolfi & Haddad, 1977).
The dominant protein was albumin with a substantial
contribution from α-fetoprotein. However, as the samples
were from aborted fetuses it is uncertain whether the state
of the fetuses would have affected the protein content of
the CSF sampled. In the newborn period CSF is sampled
in investigation of a number of pathological conditions,
but some normal values have been published; the level
in preterm infants is higher than at term and than in
adults (see Table 1 in Saunders, 1977; Bonadio, 1992;
Srinivasan et al.2012). It has been suggested that thehigher
CSF protein concentration in neonates reflects increased
permeability of the blood–brain barrier (Bonadio, 1992;
Srinivasan et al. 2012). CSF protein concentration does
not reach adult values until about 6 months after birth
(Adinolfi, 1985), which has been taken by some as the age
when the blood–brain barrier is ‘mature’ (Rodier, 1995;
Watson et al. 2006). In reality the concentration of protein
in neonatal CSF is but one of many indicators of blood–
brain or more accurately blood–CSF barrier function.
Rather than indication of a more permeable blood–brain
barrier a more critical determinant is likely to be the
turnover of CSF, which is less in the developing brain.
Adinolfi & Haddad (1977) and Adinolfi (1985) inter-
preted the high concentration of protein in human fetal
CSF as evidence that ‘permeability of the blood–CSF
barrier is ‘incomplete’ or ‘immature’ in humans; from
permeability experiments with 125I-labelled proteins in
newborn rats they drew the same conclusion (Adinoffi
& Haddad, 1977). From measurements of total protein
concentration in fetal and newborn rabbits Ramey &
Birge (1979) concluded that ‘theblood–cerebrospinal fluid
barrier to proteins begins to function by 18 to 20 days of
gestation’. From their data on total protein concentration
in CSF of chick embryos, Birge et al. (1974) concluded ‘a
specialized restrictive barrier to protein does not operate
between plasma and CSF in chick embryos of 5–10 days.’
However, Ramey & Birge 1979 make the important point
that because the turnover of CSF in the developing brain
is much less than in the adult (Bass & Lundborg, 1973;
Johanson & Woodbury, 1974), this could account for the
higher level of protein in CSF.
Transfer of plasma proteins across choroid plexus
epithelial cells. The levels ofproteins in fetal andnewborn
CSF may be set by the turnover of CSF, but there is
good experimental evidence that their entry into CSF
from plasma is a result of specific transcellular transfer
of plasma proteins across choroid plexus epithelial cells
(Dziegielewska et al. 1980b, 1991; Habgood et al. 1992;
Knott et al. 1997; Liddelow et al. 2009, 2011b). Johansson
et al. (2008) have suggested that it may be the total
amount of protein in CSF that is important as a reflection
of transport capacity rather than the concentration of
protein. Counts have been made of the number of cells in
choroid plexuses immunostained for individual proteins,
e.g. albumin, α-fetoprotein and transferrin, at different
stages of brain development in different species (Jacobsen
et al. 1982a,b, 1983; Liddelow et al. 2009). The proteins
derive from plasma and cross the plexus epithelial cells by
what appears to be a specific transfer mechanism. This has
best been studied extensively for albumin (Dziegielewska
et al. 1980b, 1991; Habgood et al. 1992; Knott et al.
1997; Liddelow et al. 2009, 2011b). Depending upon the
animal species, different choroid plexuses can distinguish
different species of albumin (Dziegielewska et al.1980b,
1991; Habgood et al. 1992; Knott et al. 1997). Thus fetal
sheep choroid plexus distinguishes between on the one
hand its own albumin and bovine albumin compared to
human albumin, which is transferred into CSF to only
about one third of the other albumins (Dziegielewska et al.
1980b, 1991) as illustrated in Fig. 8. The proportion of cells
that are immunostained for individual proteins is much
higher in species with large brains and ventricular systems.
For example in human fetuses about 35–40%of the plexus
cells in the lateral and third ventricle are positive for
albumin and this declines to about 10% at birth (Jacobsen
et al. 1982a). In fetal sheep at E30–40, 40–50% of cells in
the lateral ventricle are immunopositive for albumin, this
falls to about 1% in late gestation (Jacobsen et al. 1983)
when the brain is more mature than in human fetuses. In
Monodelphis domestica at P1 when the lateral ventricular
choroid plexus first appears, < 1% of cells are positive for
albumin. This increases to about 3% in young adults. We
have not systematically counted albumin positive cells in
rodents, but it is clear in our material that the proportion
of these cells is small in rats and mice. For total plasma
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proteins (to which albumin contributes only a fraction) in
rat embryos at E13–16, some 14–17% of cells were protein
positive and this declined to 10% by E18. The ventricular
system in rodents is larger than inMonodelphis.
A screen of transcriptomic data from mouse choroid
plexus, confirmed by single cell PCR, identified several
albumin binding molecules which were then shown to be
localized in choroid plexus epithelial cells: glycophorin A
(GYPA) and SPARC (secreted protein acidic and rich in
cysteine, also known as osteonectin/BM-40/culture-shock
protein). These albumin binding molecules might be
involved in transcellular transport of albumin in the
choroid plexus (Liddelow et al. 2012). By using an
in situ proximity ligation assay (Duolink C©) we have
been able to show intracellular co-localization of mouse
albumin and Sparc in choroid plexus cells of post-
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Figure 8. Penetration of human plasma proteins from blood
into CSF of 60-day sheep fetuses
Human plasma was injected intravenously and blood was sampled to
give an estimate of mean plasma concentration. At the times indi-
cated CSF was sampled from cisterna magna. Concentrations of
individual proteins in CSF and plasma were estimated by radial
immunodiffusion assay. Abscissa: time in hours following i.v.
injection; ordinate: CSF concentration/plasma concentration × 100.
Steady state indicates CSF/plasma ratio for naturally occurring sheep
proteins. Mean ± SEM for three to six experiments. All injected
proteins were human (h-) except for s-Alb (35S-sheep albumin) g-Alb
(goat albumin) and b-Alb (bovine albumin) measured using sheep
anti-goat or anti-bovine albumin antiserum). Experimental details
and data are from Dziegielewska et al. (1980a,1980b, 1991). α1AT,
α1-antitrypsin; AFP, α-fetoprotein; Alb, albumin; IgG,
immunoglobulins; Trf, transferrin. The sheep fetus does not possess
any IgG of its own, and hence no steady state ratio is shown. Note (i)
there is an apparent relation between molecular size and
permeability (the largest molecule, IgG, has the lowest ratio and the
smallest molecule, AFP, has the largest ratio; however, all of these
ratios except for IgG are higher than would be expected from
passive diffusion (Saunders, 1992); and (ii) albumin from different
species may have different ratios, which suggests that there is a
selective mechanism that transports proteins from plasma to CSF.
The route of protein transfer appears to be via the epithelial cells of
the choroid plexus (Jacobsen et al. 1983; Dziegielewska et al. 1991).
natal mice (Fig. 9); there was no such co-localization
for injected human albumin confirming the species
specificity of the co-localization (Liddelow et al. 2014).
An additional step in the process may be involvement of
vesicle-associatedmembraneproteins,whicharemembers
of a family of SNARE proteins (soluble NSF attachment
protein receptors), mostly involved in vesicle fusion. The
genes for three of these vesicle-associated membrane
proteins (vamp1, vamp5 and vamp8) were identified in
the transcriptomic study of mouse choroid plexus and
the localization in these cells demonstrated by immuno-
histochemistry (Liddelow et al. 2012). The ultrastructure
of a potential transcellular route for albumin in fetal
choroid plexus cells was previously demonstrated using a
combination of transmission electron microscopy (EM),
high voltage EM and gold labelling EM immuno-
cytochemistry; it has been designated as a system
of tubulocisternal endoplasmic reticulum (Møllga˚rd &
Saunders, 1975, 1977; Balslev et al. 1997a). Figure 10
and Fig. 11 illustrate how these various components
of a transcellular albumin transfer system might
operate.
Misconceptions and controversies
Continued use of the term ‘immature’ to indicate
a functional deficiency in brain barrier mechanisms.
Examples of continued use of the term ‘immature’
to indicate a functional deficiency in brain barrier
mechanisms can be found in Allen (2015), Oberdick
et al. (2016), Panfoli et al. (2016) and Amaraneni et al.
(2017). This usually turns out to be a consequence of
poor experimentation or an assumption that because a
mechanism is different from that in the adult it is in some
way deficient. In our view such differences are more likely
to reflect an importantmatch between appropriate barrier
function and particular features of the stage of brain
development. This concept has the merit of suggesting
a way forward in future research whereas dismissing
something as ‘immature’ is a dead end for both under-
standing and future enquiry. It seems reasonable towrite in
terms of maturation of blood–brain barrier mechanisms
when comparing the embryo and adult (Hupe et al.
2017), but this should not be taken to imply deficient
function. That needs to be studied in the context of the
relevant aspects of brain development in different brain
regions. At present there is not much information on this
approach as it has rarely been examined (but see above
section on ‘Proteins in fetal and newborn CSF’ and also
below).
Do the first blood vessels that grow into the brain
anlage have functionally effective tight junctions?. Or
is there ‘tightening’ of the blood–brain barrier as
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brain development proceeds (e.g. Cullen et al. 2011)?
Early developing cerebral blood vessels may not be as
fully developed in their molecular and morphological
characteristics compared to the adult as they are operating
at much lower blood pressures. This might influence the
molecular composition of junctional complexes but does
not mean that their permeability properties are different.
Ek et al. (2006) have shown that biotin ethylenediamine
(molecular mass 286 Da) and 3000 Da biotin dextran
are excluded from entering the neocortex of Monodelphis
domestica at P5 (a stage when blood vessels are first
entering the neocortex) by functionally effective tight
junctions. Umans et al. (2017) have shown that in the
CNS of zebrafish angiogenesis and blood–brain barrier
characteristics (barriergenesis) occur simultaneously as
the first blood vessels grow into the neural tissue. They
carried out some ingenious experiments in vivo in which
they compared the first appearance of the glucose trans-
porter Glut-1 and an angiogenesis marker, plvap:EGFP
(plasmalemma vesicle-associated protein: enhanced green
fluorescent protein) in a double transgenic fish. Glut-1 is
an important early characteristic of cerebral endothelial
cells, but its presence in itself does not tell anything about
the permeability of the vessels. This could be investigated
by immunostaining for a protein in plasma, as a test
of large molecule permeability or injection of a labelled
small molecule such as biotin ethylenediamine. Fleming
et al. (2013) have published permeability experiments
and EM observations at very early stages of zebrafish
development. They claim that Evans blue entered the brain
at 3 days post-fertilization (dpf) but not at 5 dpf or sub-
sequently; exclusion from the brain of sodium fluorescein
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Figure 9. Cellular distribution of mouse
albumin–SPARC (A–C) and human albumin–SPARC
(D–F)
Demonstrated by in situ Proximity Ligation Assay
(in situ PLA) signals in the lateral ventricular choroid
plexus at P2 (A and D), P10 (B and E) and adult (C and
F). Note at P2 that most of the signal was distributed
within blood vessels (BV), often associated with red
blood cells. Under this magnification it is possible to
distinguish positive signals distributed in the
basolateral cytoplasm of choroid plexus epithelial cells
(arrows). In contrast to the mouse albumin–SPARC
signal, the human albumin–SPARC signal (D) was very
rarely found and nearly always only associated with
blood vessels (BV). Only one positive signal was found
and it appears to be located in the extended
extracellular space (arrowhead). At P10 (B and E) a
very strong signal was visible for mouse
albumin–SPARC (B) in many plexus cells distributed
throughout the whole cytoplasm, blood vessels (BV)
and also in the CSF. The human albumin–SPARC signal
(E) was generally only present in blood vessels (BV) but
a very occasional signal was detected in the apparent
extended extracellular space (arrowhead). The CSF
space was negative. In the adult (C and F) a mouse
albumin–SPARC signal was distributed clearly
throughout the cytoplasm of some choroid plexus
epithelial cells (one cell marked with an asterisk). The
positive signal was also detected in the ependymal (EP)
and subependymal layers of the brain. The human
albumin–SPARC signal (F) was visible in blood vessels
(BV) but not in the CSF and only very sporadically in
the plexus epithelium (two positive red dots are
indicated by arrows). Otherwise plexus epithelial cells
(boxes) showed no in situ PLA signal. BV, blood
vessels; CSF, cerebrospinal fluid; EP, ependymal. Same
magnification, scale bar is 20 μm. From Liddelow et al.
(2014).
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Figure 10. Proposed transepithelial pathway for albumin
through choroid plexus epithelial cells
Cartoon of suggested routes of albumin transfer from plasma into
CSF across the choroid plexus epithelium. GYPA/C in the endothelial
cells may deliver albumin to the basement membrane (1) from where
it can be taken up into the plexus epithelium by GYPA/C or SPARC
(2). From here albumin may travel along a SPARC-specific pathway
through the tubulocisternal endoplasmic reticulum (3) (see Fig. 11)
and Golgi (4a), or via a VAMP-mediated pathway in vacuoles,
lysosomes or multivesicular bodies (4b). On the apical surface of the
plexus epithelium, GYPA/C may be involved in efflux of protein from
the cell into the CSF of the ventricles (5), as validated by extensive
GYPA immunoreactivity in embryonic plexus (Liddelow et al. 2012).
In the adult, the lack of immunoreactivity in the endoplasmic
reticulum and Golgi (Liddelow et al. 2012) along with increased
expression of gene products for VAMP molecules suggests that the
majority of transport possibly occurs via VAMP-mediated
vesicular/lysosomal transport such as shown in (4b). CSF,
cerebrospinal fluid; GYPA, glycophorin A; GYPC, glycophorin C;
SPARC, secreted protein acidic and rich in cysteine; VAMP,
vesicle-associated membrane proteins. Redrawn from Liddelow et al.
(2012).
was not observed until 10 dpf. The images provided are
unconvincing. Evans blue is an unsuitable marker for
blood–brain barrier studies (Saunders et al. 2015b); the
sodium fluorescein solution used (10%) is strongly hyper-
osmolar and therefore likely to be damaging to fragile
blood vessels. The EM evidence of tight junctions was
either ‘not illustrated’ or unconvincing in poor quality
micrographs. Perhaps no evidence is better than poor
quality evidence.
Van Leewen et al. (2018) have used a similar approach
to Umans et al. (2017) and report that the tight junction
protein claudin 5 is present in both cerebral endothelial
cells and choroid plexus epithelial cells. In developing
rodent choroid plexuses the only expression and immuno-
staining for claudin 5 is in blood vessels; in rodents
claudin 5 is regarded as specific for the blood–brain
barrier (Kratzer et al. 2012). Van Leewen et al. (2018)
provide additional evidence for the proposal that in
early development vascularization of the choroid plexuses
compared to that of the brain indicates that the plexuses
are likely to be a more important route of entry into the
brain early on (Johansson et al. 2008).
Ben-Zvi et al. (2014) conducted experiments in mice
at E13.5, E14.5 and E15.5 in which 10 kDa dextran
marker was injected into the liver of the embryos. In the
youngest embryos dextran was identified in cells in the
CNSparenchymaand itwas suggested that thishadcrossed
the cerebral vessel walls, thus indicating that the vessels
were permeable. It was not clear whether the route was
intercellular or transcellular. An alternative explanation
is that the dextran may have been transferred across the
choroid plexus cells into CSF and taken up from there
into parenchymal cells. At E14.5 it was reported that
there was a small amount of dextran in the interstitial
space around some vessels, although it was not apparent
in the micrographs provided. At E15.5 the dextran was
found confined to the cerebral blood vessels and on this
basis it was suggested that the blood–brain barrier in the
mouse becomes ‘functional’ at E15.5. It would require
ultrastructural studies with a suitable small marker to
confirmthis (cf. Ek et al.2003).At 5weekspost-conception
in human embryos, Møllga˚rd et al. (2017) found that
α-fetoprotein was confined to the lumen of the first blood
vessels entering the CNS tissue and the specific marker
for cerebral endothelial cell tight junctions, claudin 5, was
already present. These observations suggest the presence
of a functionally effective blood–brain barrier to protein
in the human embryo in the earliest vessels growing into
the brain parenchyma.
Is increased permeability (leakiness) to dyes and small
molecular mass markers due to ‘breakdown’ of tight
junctions?. Examples can be found in Krizbai et al.
(2005), Doherty et al. (2016) and Reinhold & Rittner
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Figure 11. Tubulocisternal endoplasmic
reticulum (TER) in fetal sheep choroid
plexus epithelial cells
A and B, electron micrographs of E60 fetal
sheep choroid plexus. Alcian blue in Krebs
solution was injected I.V. 10 min prior to
fixation. Alcian blue is electron dense and
binds to plasma albumin. Particulate
precipitate (P in A) is visible within tubular
endoplasmic reticulum (TER; dark arrows in
B), which extends close to the lateral cell
membrane (LM). JC, junctional complex
separating the lateral intercellular space
from lateral ventricular CSF. Curved arrows
in A indicate precipitated Alcian blue on
apical cell membrane; open arrows indicate
close contact of TER with apical cell
membrane, exposed to CSF. From Møllga˚rd
& Saunders (1975). C, high voltage double
impregnation thick section EM of E60 fetal
sheep choroid plexus. Note the extensive
network of TER with contacts to CSF
surface (uppermost in micrograph) and
close association of TER with Golgi complex
(G) and mitochondria (M). From Møllga˚rd &
Saunders (1977). D, electron micrograph of
ultracryosection from E60 fetal sheep
choroid plexus immunolabelled for human
(HA) 6 nm gold particles and sheep albumin
(SA) 12 nm gold particles (arrows). Gold
particles labelling each of the albumins are
colocalized within the same TER-cistern
(star) and a multivesicular body (MVB;
inset). Scale bar, 0.2 μm. From Balslev et al.
(1997a). E and F, fetal sheep choroid plexus
(E60) double impregnation technique.
Profiles of rough endoplasmic reticulum
(RER) and TER system. Note TER termination
on apical plasma membrane via a caveola
(arrowhead in F). MVB, multivesicular body;
M, mitochondrion. From Møllga˚rd &
Saunders (1977).
(2017). To demonstrate this requires electron micro-
scopy, which is rarely done. In the absence of EM
evidence, the ‘leakiness’ could as well be transcellular
via caveaoli/vesicular transport rather than being due to
disrupted tight junctions. This has been demonstrated
when electronmicroscopywas employed (Povlishock et al.
1978; Ben-Zvi et al. 2014; Krueger et al. 2015; Nahirney
et al. 2016; Andreaone et al. 2017). However, it seems
that whether or not changes in the ultrastructure of tight
junctions occur in pathological conditionsmay depend on
the nature of the disorder (Castejo´n, 2012). An additional
potential source of confusion is that it often seems to be
assumed that a change in tight junction protein or gene
expression is synonymous with tight junction dysfunction
(Sun et al. 2013; Leclerq et al. 2017). Of relevance to
blood–brain barrier development is that it seems that
transcellular transport may be important in developing
cerebral vessels but appears to be suppressed by the
C© 2018 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
J Physiol 596.23 Barrier mechanisms in the fetal and neonatal brain 5745
gene major facilitator super family domain containing 2a
(Mfsd2a) (Ben-Zvi et al. 2014). See also ‘Permeability of
the paracellular pathway’, below.
Does greater accumulation of a molecule in developing
brain and CSF reflect greater permeability of barriers
in the developing brain?. Such apparent permeability
may be due to the use of brain/plasma or CSF/plasma
ratios without allowing for the progressive decline in
blood level of a marker following injection: compare
Ferguson &Woodbury (1969) in which this was not done
and Dziegielewska et al. (1979) in which it was. These
studies gave very different values for radiolabelled inulin.
It might have been hoped that articles such as Ferguson
& Woodbury (1969) would have disappeared into the
obscurity of unsatisfactory papers, but it was cited recently
byAmaraneni et al. (2017) implying that it was evidence of
a progressive decrease in blood–brain barrier permeability
with age. The accumulation of inulin in brain and CSF in
the fetal sheep experiments of Dziegielewska et al. (1979)
did indeeddeclinewith age (although the actual levelswere
much less that in Ferguson &Woodbury (1969)), but this
decline in what we might call ‘apparent permeability’ was
more likely to have been due to themarked increase inCSF
secretion (sink effect) that occurs as brain development
progresses (see Johansson et al. 2008).
What is the role of astrocytes in formation (initiation)
and maintenance of blood–brain barrier properties?.
The controversy surrounding the possible role in the
formation of tight junctions stems from the paper of
Janzer & Raff (1987) and numerous in vitro studies of
cerebral endothelial cells, which have shown that the pre-
sence of astroctyes in the culture system was essential for
development of some features of monolayers of cerebral
endothelial cells that it was hoped would mimic essential
features of the blood–brain barrier. The relevance of
in vitro studies of these endothelial cells for under-
standing blood–brain barrier mechanisms in vivo seems
doubtful, given that cells change their properties and gene
expression when isolated (Szmydynger-Chodobska et al.
2007; Lyck et al. 2009; Zhang et al. 2016); this will not
be discussed further. Janzer & Raff (1987) claimed that
following injection of astrocytes into the anterior eye
chamber of the rat or on the chorioallantoic membrane
of the chicken embryo, blood vessels formed that were
impermeable to injected dye because of the formation of
tight junctions between the cells of what were assumed
to be blood vessels. However, demonstration of tight
junctions requires electron microscopy, which was not
performed. When this was done in a replication of
the study (Holash et al. 1993), it was shown that the
dye-containing structures were not blood vessels and
no tight junctions were observed. Unfortunately the
Janzer & Raff (1987) paper continues to be cited as
evidence of the involvement of astrocytes in the formation
of tight junctions in vessels of the developing brain
(Abbott, 2002; Engelhardt, 2003; Siegenthaler et al. 2013;
Rosas-Hernandez et al. 2018). This is perhaps an example
of when author eminence and the supposed standing of
a journal trumps high quality evidence (Vazire, 2017).
It seems to be frequently overlooked that no astrocytes
have differentiated at the time when the brain is first
vascularized and the capillaries are impermeable to even
small lipid-insoluble molecules because of the presence
of functionally effective tight junctions (Ek et al. 2006).
Furthermore, capillaries in the subarachnoid space have
tight junctions (Balslev et al. 1997b), but there are no
astrocytes in this location. Also controversial is the role
that astrocytes may play in postnatal development and
more particularly maintenance of a range of blood brain
barrier properties (Abbott, 2002; Obermeier et al. 2013;
Engelhardt & Liebner, 2014; Saunders et al. 2016a).
Permeability of the paracellular pathway. The concept
of the paracellular pathway arose from experiments of
Fro¨mter&Diamond (1972) inwhich theymeasured trans-
epithelial resistance in a variety of epithelia in vitro by
passing a microelectrode over the external surface of the
epithelium. There was a marked drop in resistance across
the epithelium when the electrode tip was over the region
between adjacent cells. It was proposed that this indicated
a low resistance pathway across the epithelium for water
and ion flow.Diamond (1974) later suggested that this was
also the route by which small lipid insoluble molecules,
such as sucrose, crossed epithelia. The concept was
later extended to cerebral endothelial cells. The physical
basis for the paracellular pathway is the tight junction
component of the junctional complex between adjacent
cells of an epithelial interface (Farquar & Palade, 1963).
Brightman & Reese, (1969) using horseradish peroxidase
and transmission EM showed that horseradish peroxides
(actually its reaction product) did not permeate through
the tight junctions of either choroid plexus epithelial
or cerebral endothelial cells. More recent studies using
small lipid insoluble molecules that are visualizable at
the EM level (286 Da biotin ethylenediamine and 10 kDa
biotin-labelled dextran) showed that these molecules did
not permeate tight junctions of cerebral endothelial or
choroid plexus epithelial cells in Monodelphis domestica,
even in the newborn period when the brain is first
vascularized and the choroid plexuses are first apparent;
rather these molecules traversed plexus epithelial cells by
a transcellular route (Ek et al. 2003, 2006; Liddelow et al.
2009). Thus in respect of small lipid-insoluble molecules,
Diamond’s (1974) proposal appears to be incorrect
although it is still widely believed as a fundamental
property of epithelia and cerebral endothelium (Abbott
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et al. 2010). In the case of water and ions there is no direct
evidence that they cross epithelial interfaces through a
paracellular pathway as proposed by Fro¨mter & Diamond
(1972) as water and ions cannot yet be visualized at
a sufficiently high resolution to demonstrate this. An
important limitation of the experiments of Fro¨mter &
Diamond (1972) is that the dimension of the tip of the
microelectrodes used was about 5 μM. This compares
to the intercellular space at the level of tight junctions,
which is measured in nanometres, if not zero where
adjacent cell membranes are fused. Thus an alternative
explanation for the low resistance pathway is that there
is an intracellular pathway close to the border of the cell
membrane between adjacent cells. Diamond (1974) seems
to have acknowledged this possibility as he suggested that
in some epithelia the low resistance pathway might be
due to ‘leaky’ cells, although he thought this would be
exceptional. The studies of Ek et al. (2003, 2006) require
independent replication, preferably in several different
species, but they indicate that the earliest vessels growing
into the brain are structurally well enough developed
for their tight junctions to be impermeable to even very
small molecules. Similarly, in the early developing choroid
plexus the paracellular route appears to be closed to small
lipid-insoluble molecules. Thus a low resistance trans-
cellular pathway across epithelial cells for ions and water,
such as in the choroid plexus, is a plausible alternative
explanation to the paracellular route envisaged by Fro¨mter
&Diamond (1972); these alternatives will only be resolved
when suitable high resolution microscopical methods
become available. The current dependence on in vitro
systems (thepermeability properties ofwhich are generally
not representative of those in intact vessels, Curry, 2005),
modelling (Curry, 2005), cartoon biology (Gunzel, 2017)
and deductions from pathological conditions (Mankertz
& Schulzke, 2007) to support the functional importance
of the paracellular pathway may be misplaced.
Different animal species used for brain barrier studies
For a large number of problems, there will be some animal of
choice on which it can be most conveniently studied (Krogh,
1929)
Effective research not only depends upon the
convenience of the species but also on its relevance to
the problem being studied. Thus the animal species to be
chosen depends to a large degree on the questions asked.
In developmental studies it is often a trade-off between
the limits imposed by the size of the species (for example
where adequate physiological monitoring is essential) and
the requirement to study as early stages of development as
possible.
Table 4 provides information about developmental
milestones and ages at which experiments have been T
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performed in the key mammalian species that have been
used for developmental brain barrier studies. We have
divided the species into four groups based on stages of
brain development at birth. Group I aremarsupial species,
which are born with a two-layered undifferentiated
neocortex; their choroid plexuses are only just beginning
to appear and all four are present within a week post-
natal. These animals are very small (10 mm crown–rump
length) at birth but have the considerable advantage
compared to eutherian mammals that they are born
at such an early stage of development that they can
be studied without having to work in utero. They also
survive much better than rodents at equivalent stages
of brain development. Tammars are seasonal breeders
and usually have only one young; they require sub-
stantial infrastructure for maintaining a colony. Mono-
delphis will breed all the year round and have multiple
young that are exposed on the mother’s abdomen; they
are pouchless marsupials. They can easily be bred within
a standard animal house, although they require a higher
room temperature and humidity than rodents (Fadem
et al. 1982). Some have questioned the value of marsupial
species for developmental studies on the grounds of lack of
research tools compared to rodents. However the genomes
of both species have now been sequenced (Mikkelsen et al.
2007; Renfree et al. 2011) and in our experience antibodies
to human antigens cross-react well with proteins in these
species.
Group II are neonatal rats and mice, which are as
suitable as marsupials for barrier studies at later stages
of development. At birth the neurogenesis is mostly
complete while gliogenesis is beginning. In utero studies
aremore difficult technically because of small size, fragility
and difficulty of maintaining fetuses in a physiologically
normal state. Group III animals are appreciably larger at
birth and more advanced in brain development. In utero
experiments are also difficult although a few studies have
been published (e.g. Bissonnette et al. 1991; Sandberg et al.
1996). Group IV is the sheep fetus, which since it was
introduced by Barcroft and Barron (Barcroft et al. 1936,
1940) has been the traditional species for a whole range
of developmental physiological studies. Sheep placenta
is made up of around 100 cotyledons, each with its
own circulation (Dawes, 1968). Thus access to the fetal
circulation can be obtained with minimal disruption of
the placental circulation, which is a significant problem in
rodents, where there is a single placenta for each embryo.
Permeability studies in fetal sheep under monitored and
reasonably well-controlled physiological conditions have
been possible as early as E50 (Evans et al. 1974). Most
blood–brain barrier studies have been conducted at older
ages (E60: Evans et al. 1974; Dziegielewska et al. 1979,
1980bb, 1991) or later (e.g. E87 to term: Stonestreet et al.
1996). The monitored studies in fetal sheep are relatively
expensive and require more space and instrumentation,
but they provide important background validation to
studies in species where monitoring has so far not been
technically possible.
Not included in Table 4 are non-mammalian species
such as chick and zebrafish embryos. These have the
considerable advantages of accessibility at very early stages
of brain development. Zebrafish have the so-far-unique
advantage of being transparent so various processes can be
visualized real-timewith time-lapsemicroscopy (Chang&
Sive, 2012; Umans et al. 2017). More detailed information
on brain development milestones in some of these species
is to be found in Clancy et al. (2001, 2007), Clowry et al.
(2010) and Semple et al. (2013).
In conclusion, because each species comeswith inherent
limitations, it is preferable to study barrier problems
in several animal species. This extends the range of
developmental ages that can be studied and provides
complimentary evidence on a particular question, rather
than mere replication. This is an approach that has been
described as ‘triangulation’ (Munafo` & Smith, 2018).
Future studies
Further work will be required to resolve the controversies
outlined above. In addition, there are several topics
that have been barely touched on in studies so far.
These include when the proposed cerebral lymphatic
system (Johnston et al. 2004; Iliff & Nedergaard, 2013)
develops (Koh et al. 2006) and whether the ‘glymphatic’
system (Plog & Nedergaard, 2017) is functional in the
developing brain. Major areas for future research are the
following.
Drugs that enter the developing brain: do they
affect brain development and behaviour?. The efflux
mechanisms summarized above limit the entry of drugs
into the adult brain. But the effectiveness of these
protective mechanisms in the developing brain when
drugs are administered to pregnant women or to neonates
is largely unknown. Systematic studies in the human fetus
that define which efflux transporters are present in the
developing brain and when they appear (e.g. Møllga˚rd
et al. 2017) are required as a prerequisite for functional
studies of these transporters in an appropriate animal
model. Fortunately it seems likely that only a limited
number of the ABC transporters are involved. Thousands
of drugs and toxins are kept out or eliminated from
the brain; this is because many drugs are substrates for
individual transporters. Thus if key drugs that are known
to be substrates for each efflux transporter are selected,
then the effectiveness of each transporter can be assessed
at different stages of brain development. However, this
assessment is complicated by a number of factors. Any
one drug may be a substrate for more than one efflux
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transporter. Many of the transporters are also functional
in the placenta. Thus placental function needs to be
taken into account when assessing the possible entry
of drugs into the brain. On the other hand for pre-
maturely born infants that have lost the protection of
the placenta early, it is possible that the brain will be
more susceptible to the entry of drugs administered in
the neonatal period. There is some evidence, although as
yet controversial, that some transporters up-regulate in
the face of continued exposure to their substrates. Thus
for pregnant women on regular medication, for example
anti-epileptics, this may affect the entry of drugs into the
fetal brain. Once it is established which classes of drugs
can enter the developing brain and when, a large field
will open up for systematic studies of the short- and
long-term consequences of drug exposure in pregnancy
and the neonatal period. At present only limited studies
have been carried out and these are often poorly designed,
resulting in unnecessary alarm in patients. To give a few
recent examples: poor quality epidemiological studies of
paracetamol in pregnancy (Stergiakouli et al. 2016, see
comments in Beale, 2017; Saunders & Habgood, 2017);
clinically improbable doses of paracetamol in pregnant
mice (Hay-Schmidt et al. 2017) and administration of
penicillin to mice during a large proportion of pregnancy
and the postnatal period (Leclerq et al. 2017) in which
there was a lack of randomization, lack of blinding
of behavioural studies, dubious statistical analysis and
dubious interpretation of results of tight junction protein
expression.
Composition, origin and functions of CSF in mammalian
embryos. It is worth emphasizing the likely importance
of CSF in the development of the CNS. Consideration of
this can conveniently be divided into two stages. (a) after
the closure of the neural tube, which traps amniotic fluid
within the tube and before choroid plexuses appear. Its
composition is subsequently modified although different
emphasis has been placed on the importance of materials
emanating from the neuropepithelium (Zappaterra et al.
2007;Chau et al. 2015) and those entering fromoutside the
CNS (Bueno et al. 2014; Gato et al. 2014). (b) the period
from differentiation of the choroid plexuses onwards.
There is evidence that proteins are transferred from the
circulating blood to the CSF across the plexus epithelial
cells (see ‘Transfer of plasma proteins across choroid
plexus epithelial cells’, above) but other constituents of
the CSF are likely to originate from the choroid plexuses
themselves or from the neuroepithelial tissues lining the
ventricular system. It is worth emphasizing that in the
first stage (after the closure of the neural tube) the
neural tissue is not vascularized and in the early period
of the second stage (from differentiation of the choroid
plexuses onwards) there is little vascularization of the
CNS; it is only after birth, for example in rodents, that
the neocortex develops most of its vasculature (Caley
& Maxwell, 1970). Thus non-vascular sources of the
constituents of CSF dominate in the early stages of brain
development. Features of brain development that have
so far been studied in the context of specific aspects
of brain development are neurogenesis (Alonso et al.
2011; Lehtinen & Walsh, 2011; Johansson, 2014) and cell
proliferation (Miyan et al. 2006; Lehtinen et al. 2011).
Zappaterra & Lehtinen (2012) have reviewed a range of
developmental processes in which CSF constituents may
be involved.
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